Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Halsey

  • News

Executive Summary

Selling ANDA for oxycodone 5 mg/acetaminophen 325 mg tablets to Mallinckrodt. Halsey received $500,000 on signing the letter of intent and expects to get "several million" dollars when deal is completed. Mallinckrodt also agrees to extend credit to Halsey for certain raw material purchases. The funds from the sale will be used to reduce Halsey's outstanding debt. The generic company announces that its banks have extended Halsey's credit agreement to Dec. 31. Under an agreement announced in April, the banks will waive certain defaults under Halsey's restructed loan agreements

Table

View full table

Tags:
Latest Headlines

Epitel Gets 510(k) Clearance On Remote EEG Technology

Valuable Health Data Sources For Medtech Industry Come A Step Closer In The EU

Rise In Class I Device Recalls A ‘Grave Concern,’ Says FDA’s Anne Reid

Discreet Gait Freezing Solution Brings Therapy With The Tap Of An Apple Watch

See All
UsernamePublicRestriction

Register

PS024888

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By